Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  CytoTools AG    T5O   DE000A0KFRJ1

Delayed Quote. Delayed  - 09/26 05:36:10 pm
9.333 EUR   -1.45%
08/30 CYTOTOOLS : DermaTools action for damages
04/27 CYTOTOOLS : DermaTools signs contracts for production by a new Germa..
02/03 CYTOTOOLS : strenghthens DermaTools Biotech GmbH with a  capital inc..
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
09/16/2016 09/21/2016 09/22/2016 09/23/2016 09/26/2016 Date
10.09(c) 9.72(c) 9.799(c) 9.47(c) 9.333(c) Last
982 825 136 806 910 Volume
+1.42% -3.67% +0.81% -3.36% -1.45% Change
More quotes
Financials (€)
Sales 2015 1,50 M
EBIT 2015 -2,60 M
Net income 2015 -2,60 M
Finance 2015 0,20 M
Yield 2015 -
Sales 2016 2,60 M
EBIT 2016 -1,70 M
Net income 2016 -1,70 M
Finance 2016 2,30 M
Yield 2016 -
P/E ratio 2015 -
P/E ratio 2016
EV / Sales2015 12,5x
EV / Sales2016 6,40x
Capitalization 18,9 M
More Financials
Company
CytoTools AG operates as a biotechnology company, which engages in developing therapeutic from research on programmed death cell.The company was founded by Dirk Kaiser and Mark-Andre Freyberg in 2000 and is headquartered in Darmstadt, Germany. 
More about the company
Latest news on CYTOTOOLS AG
08/30 CYTOTOOLS : DermaTools action for damages
08/26 DGAP-NEWS : CytoTools AG: Das Tochterunternehmen DermaTools Biotech GmbH reicht ..
07/29 DGAP-NEWS : Wechsel im Aufsichtsrat der CytoTools AG - Herr Dr. Tober legt aus..
05/23 DGAP-NEWS : CytoTools AG: Resultate aus der Phase II/III Studie zur Behandlung d..
04/27 CYTOTOOLS : DermaTools signs contracts for production by a new German manufactur..
04/22 DGAP-NEWS : DermaTools Biotech GmbH identifiziert neuen Hersteller für Wirkstoff..
02/03 CYTOTOOLS : strenghthens DermaTools Biotech GmbH with a  capital increase
02/03 CYTOTOOLS : stärkt das Tochterunternehmen DermaTools Biotech GmbH durch Kapitale..
01/26 CYTOTOOLS : klärt die Ursachen der zu geringen Wirkstoffkonzentration auf, die z..
2015 CYTOTOOLS : DermaPro retains its potential
More news
Sector news : Bio Therapeutic Drugs
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
More sector news : Bio Therapeutic Drugs
Advertisement
Chart CYTOTOOLS AG
Duration : Period :
CytoTools AG Technical Analysis Chart | T5O | DE000A0KFRJ1 | 4-Traders
Full-screen chart
Technical analysis trends CYTOTOOLS AG
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price 11,5 €
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark-Andre Freyberg CEO & Head-Investor Relations
Manfred May Chairman-Supervisory Board
Dirk Kaiser Chief Research Officer
Markus H. Weissbach Chief Medical Officer
Dieter Tober Member-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTOTOOLS AG-8.15%21
AMGEN, INC.6.90%130 813
GILEAD SCIENCES, INC.-20.33%107 381
CELGENE CORPORATION-11.23%84 821
REGENERON PHARMACEUTIC..-25.56%43 212
VERTEX PHARMACEUTICALS..-29.83%22 456
More Results